PRLD
Prelude Therapeutics Inc
NASDAQ: PRLD · HEALTHCARE · BIOTECHNOLOGY
$5.23
+22.48% today
Updated 2026-04-30
Market cap
$275.98M
P/E ratio
—
P/S ratio
22.73x
EPS (TTM)
$-1.29
Dividend yield
—
52W range
$1 – $6
Volume
0.4M
Prelude Therapeutics Inc (PRLD) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-284.50%
ROE
-99.50%
ROA
-40.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | $0.00 | $-14.68M | — | — | — |
| 2019 | $0.00 | $-27.57M | — | — | — |
| 2020 | $0.00 | $-56.93M | — | — | — |
| 2021 | $0.00 | $-110.78M | — | — | — |
| 2022 | $0.00 | $-107.34M | — | — | — |
| 2023 | $0.00 | $-121.83M | — | — | — |
| 2024 | $7.00M | $-127.17M | 100.00% | -1,995.91% | -1,816.76% |
| 2025 | $12.14M | $-99.50M | 85.91% | -861.33% | -819.59% |